{"id":391244,"date":"2015-11-17T00:00:00","date_gmt":"2015-11-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu1415-biopharma-parkinsons-disease-market-access-in-the-complex-parkinsons-disease-market-physician\/"},"modified":"2026-04-23T11:43:17","modified_gmt":"2026-04-23T11:43:17","slug":"pforeu1415-biopharma-parkinsons-disease-market-access-in-the-complex-parkinsons-disease-market-physician","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu1415-biopharma-parkinsons-disease-market-access-in-the-complex-parkinsons-disease-market-physician\/","title":{"rendered":"Parkinson\u2019s Disease (Market Access in the Complex Parkinson\u2019s Disease Market) | Physician &#038; Payer Forum | EU5 | 2015"},"content":{"rendered":"<p><em>European Physician and Payer Perspective on Current Mainstays and Novel Entrants in the Age of Austerity <\/em><br \/>\nParkinson\u2019s disease (PD) is a debilitating chronic neurodegenerative disease affecting more than one million people in the five major European pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom; EU5). At the core of PD treatment is long-generic standard of care levodopa (multiple brands, generics), but drugs from several other classes, including dopamine agonists and MAO-B inhibitors, have helped improve patients\u2019 quality of life and proved commercially successful. In early 2015, Xadago (Newron\/Zambon), a third-in-class MAO-B inhibitor, became one of the first new drugs approved for PD in Europe in many years; the pipeline further includes several late-stage agents that have the potential to reach the market within the next three years. These new agents will enter an increasingly cost-sensitive environment, and marketers will need to provide clear evidence of clinical improvements and\/or cost benefits over well-entrenched, often generically available standards-of-care to receive a favorable health technology assessment (HTA) and command premium pricing.<\/p>\n","protected":false},"template":"","class_list":["post-391244","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-parkinsons-disease","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391244\/revisions"}],"predecessor-version":[{"id":576917,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391244\/revisions\/576917"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}